Abstract
This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.
| Translated title of the contribution | Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for læger |
| Volume | 171 |
| Issue number | 47 |
| Pages (from-to) | 3435-7 |
| Number of pages | 3 |
| ISSN | 0041-5782 |
| Publication status | Published - 16 Nov 2009 |